Simulations Plus (NASDAQ:SLP) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Simulations Plus (NASDAQ:SLP) issued its earnings results on Sunday. The technology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a return on equity of 24.44% and a net margin of 22.96%.

Shares of NASDAQ:SLP traded down $8.28 during trading on Tuesday, reaching $71.05. The company had a trading volume of 23,687 shares, compared to its average volume of 287,831. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 152.38, a price-to-earnings-growth ratio of 7.63 and a beta of -0.17. The stock’s fifty day moving average price is $65.06 and its 200 day moving average price is $65.43. Simulations Plus has a fifty-two week low of $26.00 and a fifty-two week high of $83.78.

In other news, Director Walter S. Woltosz sold 24,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $72.71, for a total value of $1,745,040.00. Following the transaction, the director now owns 4,659,614 shares of the company’s stock, valued at $338,800,533.94. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Shawn Oconnor sold 6,381 shares of the business’s stock in a transaction that occurred on Monday, November 30th. The shares were sold at an average price of $56.50, for a total value of $360,526.50. The disclosure for this sale can be found here. In the last three months, insiders sold 64,881 shares of company stock worth $4,347,992. Corporate insiders own 31.57% of the company’s stock.

SLP has been the topic of several research analyst reports. Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating in a research report on Tuesday. Raymond James started coverage on Simulations Plus in a research report on Friday, October 16th. They set an “outperform” rating and a $95.00 target price on the stock. Zacks Investment Research lowered Simulations Plus from a “hold” rating to a “sell” rating in a research report on Thursday, November 19th. Oppenheimer lifted their price target on Simulations Plus from $79.00 to $85.00 in a research report on Tuesday. Finally, BidaskClub raised Simulations Plus from a “hold” rating to a “buy” rating in a research report on Wednesday, December 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $81.60.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.

Featured Story: Understanding Market Liquidity

Earnings History for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit